Roth Capital Has Bearish Estimate for Accuray Q2 Earnings

Accuray Incorporated (NASDAQ:ARAY) – Research analysts at Roth Capital decreased their Q2 2025 earnings per share estimates for shares of Accuray in a note issued to investors on Tuesday, November 19th. Roth Capital analyst J. Wittes now forecasts that the medical equipment provider will post earnings per share of $0.00 for the quarter, down from their prior estimate of $0.01. The consensus estimate for Accuray’s current full-year earnings is $0.01 per share. Roth Capital also issued estimates for Accuray’s Q4 2025 earnings at $0.05 EPS.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04). The firm had revenue of $101.55 million during the quarter, compared to the consensus estimate of $98.10 million. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. During the same quarter last year, the company posted ($0.03) EPS.

Separately, StockNews.com cut Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Accuray Stock Performance

Shares of ARAY opened at $1.83 on Thursday. The company has a market cap of $184.03 million, a PE ratio of -10.76 and a beta of 1.40. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. Accuray has a 12-month low of $1.40 and a 12-month high of $3.05. The stock has a 50-day moving average price of $1.85 and a 200-day moving average price of $1.83.

Hedge Funds Weigh In On Accuray

A number of large investors have recently modified their holdings of ARAY. Foundry Partners LLC increased its stake in Accuray by 51.3% in the 3rd quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock worth $3,937,000 after purchasing an additional 741,900 shares during the period. Armistice Capital LLC bought a new stake in shares of Accuray in the 2nd quarter worth approximately $910,000. Los Angeles Capital Management LLC bought a new stake in shares of Accuray in the 3rd quarter worth approximately $418,000. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Accuray by 489.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider’s stock worth $500,000 after buying an additional 230,695 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of Accuray by 143.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 384,944 shares of the medical equipment provider’s stock worth $693,000 after buying an additional 226,602 shares during the last quarter. 64.08% of the stock is owned by hedge funds and other institutional investors.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.